STE · Steris PLC - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $5.46B | $5.14B | $4.96B | $4.59B | $3.11B | $3.03B |
| Cost of Revenue | $3.06B | $2.92B | $2.80B | $2.57B | $1.71B | $1.71B |
| Gross Profit | $2.40B | $2.22B | $2.16B | $2.02B | $1.34B | $1.32B |
| R&D | $107.65M | $103.68M | $101.58M | $87.94M | $66.33M | $65.55M |
| SG&A | $1.33B | $1.25B | $1.30B | $1.50B | $731.32M | $716.73M |
| Total Operating Expenses | $1.54B | $1.38B | $1.89B | $1.59B | $794.73M | $782.95M |
| D&A | $476.21M | $565.24M | $552.90M | $553.10M | $219.24M | $197.24M |
| Operating Income | $866.64M | $836.12M | $268.19M | $425.62M | $548.37M | $536.97M |
| Interest Expense | $144.35M | $144.35M | $107.99M | $89.59M | $37.18M | $40.28M |
| Income Tax | $184.65M | $149.53M | $51.53M | $71.63M | $120.66M | $90.88M |
| Net Income | $614.64M | $378.24M | $107.03M | $243.89M | $397.40M | $407.61M |
| EPS - Basic | $6.24 | $3.83 | $1.07 | $2.50 | $4.66 | $4.81 |
| EPS - Diluted | $6.20 | $3.81 | $1.07 | $2.48 | $4.63 | $4.76 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $171.70M | $207.02M | $208.36M | $319.58M | $220.53M | $319.58M |
| Accounts Receivable | $1.04B | $1.01B | $928.32M | $799.04M | $609.41M | $586.48M |
| Inventory | $581.33M | $674.53M | $695.49M | $575.00M | $315.07M | $248.26M |
| Accounts Payable | $280.77M | $251.72M | $279.62M | $225.74M | $156.95M | $149.34M |
| Current Assets | $2.00B | $2.87B | $2.01B | $1.88B | $1.21B | $1.21B |
| Total Assets | $10.15B | $11.06B | $10.82B | $11.42B | $6.57B | $5.43B |
| Current Liabilities | $1.02B | $931.13M | $861.84M | $922.22M | $577.92M | $503.61M |
| Long-term Debt | $1.92B | $3.12B | $3.02B | $2.95B | $1.65B | $1.15B |
| Total Liabilities | $3.53B | $4.75B | $4.73B | $4.88B | $2.68B | $2.02B |
| Stockholders' Equity | $6.60B | $6.30B | $6.08B | $6.53B | $3.88B | $3.39B |
| Retained Earnings | $2.48B | $2.09B | $1.91B | $2.00B | $1.94B | $1.65B |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.15B | $973.27M | $756.95M | $684.81M | $689.64M | $590.56M |
| Investing Cash Flow | $388.77M | ($887.36M) | ($383.33M) | ($666.56M) | ($1.15B) | ($319.74M) |
| Financing Cash Flow | ($1.57B) | ($85.19M) | ($498.72M) | $115.83M | $345.62M | ($163.15M) |
| CapEx | $370.09M | $360.33M | $361.97M | $287.56M | $239.26M | $214.52M |
| Free Cash Flow | $778.00M | $612.95M | $394.98M | $397.25M | $450.38M | $376.04M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 44.0% | 43.2% | 43.6% | 44.0% | 43.2% | 43.5% |
| Operating margin | 15.9% | 16.3% | 5.4% | 9.3% | 17.6% | 17.7% |
| EBITDA margin | 24.6% | 27.3% | 16.6% | 21.3% | 24.7% | 24.2% |
| Net margin | 11.3% | 7.4% | 2.2% | 5.3% | 12.8% | 13.4% |
| Free cash flow margin | 14.3% | 11.9% | 8.0% | 8.7% | 14.5% | 12.4% |
| FCF / Net income | 1.27 | 1.62 | 3.69 | 1.63 | 1.13 | 0.92 |
| R&D / Revenue | 2.0% | 2.0% | 2.0% | 1.9% | 2.1% | 2.2% |
| SG&A / Revenue | 24.4% | 24.4% | 26.2% | 32.8% | 23.5% | 23.6% |
| Effective tax rate | 23.1% | 28.3% | 32.5% | 22.7% | 23.3% | 18.2% |
| Return on assets | 6.1% | 3.4% | 1.0% | 2.1% | 6.0% | 7.5% |
| Return on equity | 9.3% | 6.0% | 1.8% | 3.7% | 10.2% | 12.0% |
| Return on invested capital | 7.8% | 6.4% | 2.0% | 3.5% | 7.6% | 9.7% |
| Liquidity | ||||||
| Current ratio | 1.96 | 3.08 | 2.33 | 2.04 | 2.10 | 2.40 |
| Quick ratio | 1.39 | 2.36 | 1.53 | 1.41 | 1.55 | 1.91 |
| Cash ratio | 0.17 | 0.22 | 0.24 | 0.35 | 0.38 | 0.63 |
| Leverage | ||||||
| Debt / Equity | 0.29 | 0.50 | 0.50 | 0.45 | 0.43 | 0.34 |
| Debt / Assets | 0.19 | 0.28 | 0.28 | 0.26 | 0.25 | 0.21 |
| Debt / EBITDA | 1.43 | 2.23 | 3.68 | 3.01 | 2.15 | 1.57 |
| Interest coverage | 6.0x | 5.8x | 2.5x | 4.8x | 14.7x | 13.3x |
| Equity multiplier | 1.54 | 1.76 | 1.78 | 1.75 | 1.69 | 1.60 |
| Liabilities / Assets | 0.35 | 0.43 | 0.44 | 0.43 | 0.41 | 0.37 |
| Efficiency | ||||||
| Asset turnover | 0.54 | 0.46 | 0.46 | 0.40 | 0.47 | 0.56 |
| Inventory turnover | 5.26 | 4.33 | 4.02 | 4.47 | 5.43 | 6.89 |
| Days sales outstanding | 70d | 72d | 68d | 64d | 72d | 71d |
| Days inventory outstanding | 69d | 84d | 91d | 82d | 67d | 53d |
| Days payable outstanding | 34d | 31d | 36d | 32d | 33d | 32d |
| Cash conversion cycle | 106d | 124d | 123d | 113d | 105d | 92d |
| Valuation | ||||||
| P / E | 40.9x | 59.0x | 205.5x | 97.5x | 41.1x | 29.4x |
| P / B | 3.8x | 3.5x | 3.6x | 3.6x | 4.2x | 3.5x |
| P / S | 4.6x | 4.3x | 4.4x | 5.2x | 5.3x | 4.0x |
| EV / EBITDA | 20.0x | 18.0x | 30.3x | 27.0x | 23.2x | 17.5x |
| Growth | ||||||
| Revenue growth (YoY) | 6.2% | 3.6% | 8.1% | 47.5% | 2.5% | 16.0% |
| Revenue CAGR (3y) | 6.0% | 18.3% | 17.8% | 20.6% | - | - |
| Revenue CAGR (5y) | 12.5% | 14.5% | - | - | - | - |
| Gross profit growth (YoY) | 8.3% | 2.7% | 7.1% | 50.1% | 1.8% | 28.6% |
| Operating income growth (YoY) | 3.7% | 211.8% | -37.0% | -22.4% | 2.1% | 137.4% |
| Net income growth (YoY) | 62.5% | 253.4% | -56.1% | -38.6% | -2.5% | 270.7% |
| EPS growth (YoY) | 62.7% | 256.1% | -56.9% | -46.4% | -2.7% | 271.9% |
| EPS CAGR (3y) | 35.7% | -6.3% | -39.2% | 24.7% | - | - |
| EPS CAGR (5y) | 5.4% | 24.4% | - | - | - | - |
| FCF growth (YoY) | 26.9% | 55.2% | -0.6% | -11.8% | 19.8% | 49.7% |
| FCF CAGR (5y) | 15.7% | 19.5% | - | - | - | - |
| Book value growth (YoY) | 4.8% | 3.7% | -7.0% | 68.3% | 14.4% | 5.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2026-03-31.
Business segments
$5.94B totalHealthcare Segment$4.21B · 70.9%
Applied Sterilization Technologies$1.14B · 19.2%
Life Science Member$588.80M · 9.9%
Product / service
$10.14B totalProduct$3.06B · 30.2%
Service$2.88B · 28.3%
Servicerevenues$1.62B · 15.9%
Consumablerevenues$1.50B · 14.8%
Capitalequipmentrevenues$1.10B · 10.8%
Geographic
$5.94B totalUS$4.33B · 73.0%
Otherforeignlocations$1.49B · 25.2%
IE$108.50M · 1.8%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.86
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
8/9
Strong
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Comparing STERIS plc against the 5 most active filers in the same SIC group.
Dividends
$1.83/share trailing 12 months · -17.9% YoY
| Ex-date | Per share |
|---|---|
| Feb 17, 2026 | $0.6300 |
| Sep 4, 2025 | $0.6300 |
| Jun 10, 2025 | $0.5700 |
| Feb 20, 2025 | $0.5700 |
| Nov 19, 2024 | $0.5700 |
| Sep 5, 2024 | $0.5700 |
| Jun 12, 2024 | $0.5200 |
| Feb 22, 2024 | $0.5200 |
| Nov 20, 2023 | $0.5200 |
| Sep 5, 2023 | $0.5200 |
| Jun 13, 2023 | $0.4700 |
| Feb 23, 2023 | $0.4700 |
| Nov 21, 2022 | $0.4700 |
| Sep 6, 2022 | $0.4700 |
| Jun 13, 2022 | $0.4300 |
| Feb 24, 2022 | $0.4300 |
| Nov 22, 2021 | $0.4300 |
| Sep 2, 2021 | $0.4300 |
| May 27, 2021 | $0.4000 |
| Feb 23, 2021 | $0.4000 |
| Nov 23, 2020 | $0.4000 |
| Aug 26, 2020 | $0.4000 |
| Jun 11, 2020 | $0.3700 |
| Feb 24, 2020 | $0.3700 |